Ono Pharmaceutical Co., Ltd.
4528.T · JPX
3/31/2025 | 3/31/2024 | 3/31/2023 | 3/31/2022 | |
|---|---|---|---|---|
| Revenue | ¥486,871 | ¥502,672 | ¥447,187 | ¥361,361 |
| % Growth | -3.1% | 12.4% | 23.8% | – |
| Cost of Goods Sold | ¥147,950 | ¥127,126 | ¥110,062 | ¥93,511 |
| Gross Profit | ¥338,921 | ¥375,546 | ¥337,125 | ¥267,850 |
| % Margin | 69.6% | 74.7% | 75.4% | 74.1% |
| R&D Expenses | ¥149,866 | ¥112,377 | ¥95,344 | ¥75,879 |
| G&A Expenses | ¥91,568 | ¥73,370 | ¥68,806 | ¥62,623 |
| SG&A Expenses | ¥122,219 | ¥97,389 | ¥86,643 | ¥74,119 |
| Sales & Mktg Exp. | ¥30,651 | ¥24,019 | ¥17,837 | ¥11,496 |
| Other Operating Expenses | ¥7,089 | ¥2,677 | ¥13,174 | ¥2,938 |
| Operating Expenses | ¥279,174 | ¥212,443 | ¥195,161 | ¥152,936 |
| Operating Income | ¥59,747 | ¥163,103 | ¥141,963 | ¥114,914 |
| % Margin | 12.3% | 32.4% | 31.7% | 31.8% |
| Other Income/Exp. Net | -¥419 | ¥631 | ¥1,569 | -¥9,889 |
| Pre-Tax Income | ¥59,328 | ¥163,734 | ¥143,532 | ¥105,025 |
| Tax Expense | ¥9,163 | ¥35,694 | ¥30,619 | ¥24,340 |
| Net Income | ¥50,047 | ¥127,977 | ¥112,723 | ¥80,519 |
| % Margin | 10.3% | 25.5% | 25.2% | 22.3% |
| EPS | 106.55 | 266.57 | 230.85 | 162.19 |
| % Growth | -60% | 15.5% | 42.3% | – |
| EPS Diluted | 106.41 | 266.6 | 230.79 | 162.16 |
| Weighted Avg Shares Out | 470 | 480 | 1,465 | 1,490 |
| Weighted Avg Shares Out Dil | 470 | 480 | 1,465 | 1,490 |
| Supplemental Information | – | – | – | – |
| Interest Income | ¥4,774 | ¥4,027 | ¥2,478 | ¥2,710 |
| Interest Expense | ¥5,318 | ¥229 | ¥913 | ¥874 |
| Depreciation & Amortization | ¥26,894 | ¥18,140 | ¥17,451 | ¥17,721 |
| EBITDA | ¥91,540 | ¥182,103 | ¥161,896 | ¥122,827 |
| % Margin | 18.8% | 36.2% | 36.2% | 34% |